Herpes Virus Infections

  • D. Brigden
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 87 / 2)

Abstract

Virology is a rapidly advancing science which is now beginning to pay clear dividends in terms of our understanding of the relationship betwen viruses and their host cells and in providing more rational ways of developing major therapeutic advances. Since the first viruses to be readily tackled by chemotherapy are members of the Herpesviridae this chapter will confine itself to a discussion of the biology of this fascinating group and our attempts at the therapeutic control of the human diseases these cause.

Keywords

Influenza Interferon Thymidine Nash Encephalitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Balfour HH, Bean B, Laskin OL, Ambinder RF, Meyers JD, Wade JC, Zaia JA et al. (1983) Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 308:1448–1453PubMedCrossRefGoogle Scholar
  2. Bean B, Braun C, Balfour HH (1982) Acyclovir therapy for acute herpes zoster. Lancet 2:118–121PubMedCrossRefGoogle Scholar
  3. Blyth WA, Habour DA, Hill TJ (1980) Effect of acyclovir on recurrence of hepres simplex skin lesions sin mice. J Gen Virol 48:417–419PubMedCrossRefGoogle Scholar
  4. Brigden D, Fowle A, Rosling A (1980) Acyclovir, a new antiherpetic drug: early experience in man with systemically administered drug. In: Collier LH (ed) Developments in antiviral therapy. Academic, Oxford, pp 53–62Google Scholar
  5. Brigden D, Bye A, Fowle ASE, Rogers H (1981 a) Human pharmacokinetics of acyclovir (an antiviral agent) following rapid intravenous injection. J Antimicrob Chemother 7:399–404PubMedCrossRefGoogle Scholar
  6. Brigden D, Fiddian P, Rosling AE, Ravenscroft T (1981 b) Acyclovir — a review of the preclinical and early clinical data of a new antiherpes drug. Antiviral Res 1:203–212PubMedCrossRefGoogle Scholar
  7. Bryson Y, Dillon M, Lovett M, Acuna G, Taylor S, Cherry J, Johnson L et al. (1983) Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. N Engl J Med 308:916–921PubMedCrossRefGoogle Scholar
  8. Burns WH, Sarai R, Santos GW, Laskin OL, Leitman PS, McLaren C, Barry DW (1982) Isolation and characterisation of resistant herpes simplex virus after acyclovir therapy. Lancet 1:421–423PubMedCrossRefGoogle Scholar
  9. Cook ML, Stevens JG (1973) Pathogenesis of herpetic neuritis and ganglionitis in mice: evidence of intra-axonal transport of infection. Infect Immun 7:272–288PubMedGoogle Scholar
  10. Corey L, Nahmias AJ, Guinan ME, Benedetti J, Critchlow C, Holmes KK (1982) A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med 306:1313 – 1319PubMedCrossRefGoogle Scholar
  11. Corey L, Fife KH, Benedetti K, Winter CA, Fahnlander A, Connor JD, Hintz MA, Holmes KK (1983) Intravenous acyclovir for the treatment of primary genital herpes. Ann Intern Med 98:914–921PubMedGoogle Scholar
  12. Crumpacker CS, Schnipper LE, Marlowe SI, Kowalsky PN, Hershey BJ, Levin MJ (1982) Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med 306:343–346PubMedCrossRefGoogle Scholar
  13. De Clercq E, Degreef H, Wildiers J, de Jonge G, Drochmans A, Deschamps J, de Somer P (1980) Oral (E)-5-(2-bromovinyl)-2-deoxyuridine in severe herpes zoster. Br Med J 281:1178PubMedCrossRefGoogle Scholar
  14. Dekker C, Ellis MN, McLaren C, Hunter G, Rogers J, Barry DW (1983) Virus resistance in clinical practice. J Antimicrob Chemother 12B:137–152Google Scholar
  15. De Miranda P, Whitley RJ, Blum MR, Keeney RE, Barton N, Cochetto DM, Good S et al. (1979) Acyclovir kinetics after intravenous infusion. Clin Pharmacol Ther 26:718–728PubMedGoogle Scholar
  16. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ (1977) Selectivity of action of an antiherpetic agent 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 74:5716–5720PubMedCrossRefGoogle Scholar
  17. Fiddian AP, Yeo JM, Stubbings R, Dean D (1983) Successful treatment of herpes labialis with topical acyclovir. Br Med J 286:1699–1701CrossRefGoogle Scholar
  18. Field HJ, Darby G (1980) Pathogenicity in mice of strains of herpes simplex virus which are resistant in vitro and in vivo. Antimicrob Agents Chemother 17:209–216PubMedGoogle Scholar
  19. Field HJ, Bell SE, Elion GB, Nash AA, Wildy P (1979) Effects of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother 15:554–561PubMedGoogle Scholar
  20. Field HJ, Darby G, Wildy P (1980) Isolation and characterisation of acyclovir resistant mutants of herpes simplex virus. J Gen Virol 49:115–124PubMedCrossRefGoogle Scholar
  21. Furman PA, St Clair MH, Fyfe JA, Rideout JL, Keller PM, Elion GB (1979) Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl) guanine and its triphosphate. J Virol 32:72–77PubMedGoogle Scholar
  22. Gluckman E, Lotsberg J, Devargie A, Zhao A, Zhao XM, Melo R, Gomez-Morales M, Nebout T et al. (1983) Prohylaxis of herpes infections after bone marrow transplantation by oral acyclovir. Lancet 2:706–708PubMedCrossRefGoogle Scholar
  23. Hann IM, Prentice HG, Blacklock HA, Ross MGR, Brigden D, Rosling AE, Burke C et al. (1983) Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. Br Med J 287:384–388CrossRefGoogle Scholar
  24. Heidelburger C, King DH (1979) Trifluorothymidine. Pharmacol Ther 6:427–442CrossRefGoogle Scholar
  25. Jones BR, Coster DJ, Fison PN, Thompson GM, Cobo LM, Falcon MG (1979) Efficacy of acycloguanosine against herpes simplex corneal ulcers. Lancet 1:243–244PubMedCrossRefGoogle Scholar
  26. Juel-Jensen BE, MacCullum FO (1972) Herpes simplex, varicella and zoster. Heinemann, LondonGoogle Scholar
  27. Kaufman HE, Martola EL, Dohlamnm CH (1962) Use of 5-iodo-2’-deoxyuridine (IDU) in treatment of herpes simplex keratitis. Arch Ophthalmol 68:235–239PubMedCrossRefGoogle Scholar
  28. Kinghorn GR, Barton IG, Potter CW, Fiddian AP (1983) Oral acyclovir prophylaxis of recurrent genital herpes (Abstr 185). 5th International Meeting of the International Society for STD Research, SeattleGoogle Scholar
  29. Klein RJ, Freidman-Kein AE, de Stefano E (1979) Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine. Antimicrob Agents Chemother 15:723–729PubMedGoogle Scholar
  30. McGill J, MacDonald DR, Fall C, McKendrick GDW, Copplestone A (1983) Intravenous acyclovir in acute herpes zoster infection. J Infect 6:157–161PubMedCrossRefGoogle Scholar
  31. McKendrick MW, McGill JI, Bell AM, Hickmott E, Burke C (1984) Oral acyclovir for herpes zoster. Lancet 2:925PubMedCrossRefGoogle Scholar
  32. Merigan TC, Rand KH, Pollard RB, Abdallah PS, Jordon GW, Fried RP (1978) Human leukocyte interferon for the treatment of herpes zoster patients with cancer. N Engl J Med 298:981–987PubMedCrossRefGoogle Scholar
  33. Meyers JD, Wade JC, Mitchell CD, Aral R, Leitman PS, Durak DT, Levin MJ et al. (1982) Multicentre collaborative trial of intravenous acyclovir for the treatment of mucocutaneous HSV infection in the compromised host. Am J Med 73(1A):229–235PubMedCrossRefGoogle Scholar
  34. Mindel A, Adler MW, Sutherland S, Fiddian AP (1982) Intravenous acyclovir treatment for primary genital herpes. Lancet 1:697–700PubMedCrossRefGoogle Scholar
  35. Mindel A, Weiler IVD, Faherty A, Sutherland S, Hindlay D, Fiddian AP, Adler MW (1984) Prophylactic oral acyclovir in recurrent genital herpes. Lancet 2:57–59PubMedCrossRefGoogle Scholar
  36. Mitchell CD, Bean B, Gentry SR, Groth KE, Boen JR, Balfour HH (1981) Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet 1:1389–1392PubMedCrossRefGoogle Scholar
  37. Nilsen AE, Aasen T, Halsos AM, Kinge BR, Tjøtta EAL, Wikström K, Fiddian AP (1982) Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 2:571–573PubMedCrossRefGoogle Scholar
  38. Pavan-Langston D, Dohlman CH (1972) A double blind clinical study of adenine arabino-side therapy of viral keratoconjunctivitis. Am J Ophthalmol 74:81–88PubMedGoogle Scholar
  39. Peterslund NA, Seyer-Hansen K, Ipsen J, Esmann V, Schonheyder H, Juhl H (1981) Acyclovir in herpes zoster. Lancet 2:827–830PubMedCrossRefGoogle Scholar
  40. Prentice HG (1983) Use of acyclovir for prophylaxis of herpes infections in severely immunocompromised patients. J Antimicrob Chemother 12B: 153–159Google Scholar
  41. Reichman RC, Badger GJ, Mertz GJ, Corey L, Richmann DD, Connor JD, Redfield D et al. (1984) Treatment of recurrent genital herpes simplex infection with oral acyclovir: a controlled trial. JAMA 251:2103–2107PubMedCrossRefGoogle Scholar
  42. Sarai R, Burns WH, Laskin OL, Santos GW, Leitmann PS (1981) Acyclovir prophylaxis of herpes simplex virus infections, a randomised double-blind, controlled trial in bone marrow transplant recipients. N Engl J Med 305:63–67CrossRefGoogle Scholar
  43. Skoldenberg B, Forsgren M, Alestig K, Bergstrom T, Burman L, Dahlquist E, Forkman A et al. (1984) Acyclovir versus vidarabine in herpes simplex encephalitis. Lancet 2:707–711PubMedCrossRefGoogle Scholar
  44. Straus SE; Takiff HE, Seidlin M, Bachrach S, Lininger L, di Giovanna JJ, Western KA et al. (1984) Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir. J Med 310:1545–1550Google Scholar
  45. Wade JC, Newton B, Flournoy N, Meyers JD (1984) Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplant. Ann Intern Med 100:823–828PubMedGoogle Scholar
  46. Wellings PC, Audry PN, Borz FH, Jones BR, Brown DC, Kaufman HE (1972) Clinical evaluaton of trifluorothymidine in the treatment of herpes simplex corneal ulcers. Am J Ophthalmol 73:932–942PubMedGoogle Scholar
  47. Whitley RJ, Alford CA (1981) Parenteral antiviral chemotherapy of human herpesviruses. In: Nahmias AJ, Dowdle WR, Shinazi RF (eds) The human herpesviruses. Elsevier, New York, pp 478–490Google Scholar
  48. Whitley RJ, Chien LT, Dolin R, Galasso GJ, Alford C (1976) Adenine arabinoside therapy of herpes zoster in the immunosuppressed NIAID collaborative antiviral study. N Engl J Med 294:1193–1199PubMedCrossRefGoogle Scholar
  49. Whitley RJ, Soong S, Dolin R, Galasso GJ, Chien LT, Alford C (1978) Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. N Engl J Med 297:289–294CrossRefGoogle Scholar
  50. Whitley R, Alford C, Hess F, Buchanan R (1980) Vidarabine: a preliminary review of its pharmacological properties and therapeutic use. Drugs 20:267–282PubMedCrossRefGoogle Scholar
  51. Whitley RJ, Soong S, Kirsch MS, Karchmer AW, Dolin R, Galasso G, Dunnick J, Alford CA (1981) Herpes simplex encephalitis. Vidarabine therapy and diagnostic problems. N Engl J Med 304:313–318PubMedCrossRefGoogle Scholar
  52. Wildenhoff KE, Ipsen J, Esmann V, Ingemann-Fensen J, Hjelm Poulsen J (1979) Treatment of herpes zoster with idoxuridine ointment, including a multivariate analysis of symptoms and signs. Scand J Infect Dis 11:1–9PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • D. Brigden

There are no affiliations available

Personalised recommendations